Using antigen-specific B cells to combine antibody and T cell–based cancer immunotherapy

Cancer Immunology Research

Volumn 5, Issue 9, 2017, Pages 730-743

  Wennhold, Kerstin ^a   Thelen, Martin ^a   Schlößer, Hans Anton ^a   Haustein, Natalie ^a   Reuter, Sabrina ^a   Garcia Marquez, Maria ^a   Lechner, Axel ^a   Kobold, Sebastian ^b   Rataj, Felicitas ^b   Utermöhlen, Olaf ^a   Chakupurakal, Geothy ^a   Theurich, Sebastian ^a   Hallek, Michael ^a   Abken, Hinrich ^a,c   Shimabukuro Vornhagen, Alexander ^a   Von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; DOPACHROME TAUTOMERASE; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 21; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NY ESO 1 ANTIGEN; SYNDECAN 1; TETRAMER; TUMOR ANTIGEN; CD40 ANTIGEN; INTERLEUKIN DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CELLULAR IMMUNITY; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; FEEDER CELL; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; ANTIGEN PRESENTING CELL; DENDRITIC CELL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CD40 ANTIGENS; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERLEUKIN-4; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85028523770     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0236     Document Type: Article

References (46)

1. Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med 2016;21:125–33.
2. Wolchok Kluger, Callahan Postow, Gordon Segal, et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). ASCO. Chicago2013.
3. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–9.
4. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319–25.
5. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757–65.
6. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63: 2836–43.
7. Theurich S, Malcher J, Becker HJ, Chemnitz JM, Liebig TM, Shimabukuro-Vornhagen A, et al. Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells. Blood 2011;118:5979–80.
8. von Bergwelt-Baildon M, Maecker B, Menezes I, Nadler LM, Schultze JL. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Research 2004;64:4055;
9. erratum: von Bergwelt-Baildon M, Maecker B, Menezes I, Nadler LM, Schultze JL. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Research 2004;64:7181.
10. Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, Zeidler R, et al. Conditional immortalization of human B cells by CD40 ligation. PLoS One 2008;3:e1464.
11. Klein-Gonzalez N, Wennhold K, Balkow S, Kondo E, Bolck B, Weber T, et al. In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. Oncoimmunology 2015;4:.
12. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011;17:4987–95.
13. Wennhold K, Weber TM, Thelen M, Garcia-Marquez M, Chakupurakal G, Klein-Gonzalez N, et al. CD40-activated B cells induce antitumor immunity in vivo. Oncotarget 2017;8:27740–53.
14. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612–6.
15. Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, Kochanek M, Weber T, Wennhold K, et al. A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. Cytotherapy 2014;16:1537–44.
16. Liebig TM, Fiedler A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Murine model of CD40-activation of B cells. J Vis Exp 2010;5:pii:1734.
17. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Nat Cancer Inst 2015;107:pii:djv146.
18. Franz B, May KF Jr., Dranoff G, Wucherpfennig K. Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood 2011;118:348–57.
19. Singer DF, Linderman JJ. The relationship between antigen concentration, antigen internalization, and antigenic complexes: modeling insights into antigen processing and presentation. J Cell Biol 1990;111:55–68.
20. Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 1998;8:751–9.
21. Zimmermann VS, Rovere P, Trucy J, Serre K, Machy P, Forquet F, et al. Engagement of B cell receptor regulates the invariant chain-dependent MHC class II presentation pathway. J Immunol 1999;162:2495–502.
22. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3:867–78.
23. von Bergwelt-Baildon M Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006;107:2786–9.
24. Klein-Gonzalez N, Wennhold K, Balkow S, Kondo E, Bolck B, Weber T, et al. In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. Oncoimmunology 2015;4:e1038684.
25. Okada T, Miller MJ, Parker I, Krummel MF, Neighbors M, Hartley SB, et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005;3:e150.
26. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011;128:897–907.
27. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600–9.
28. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819–29.
29. Marits P, Zirakzadeh AA, Sherif A, Winqvist O. The many flavors of tumor-associated B cells. Oncoimmunology 2013;2:e25237.
30. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol 2013;34:169–73.
31. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015;521:99–104.
32. Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Therapy 2008; 15:955–65.
33. Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Br J Haematol 2001;113:455–60.
34. Ward SM, Phalora P, Bradshaw D, Leyendeckers H, Klenerman P. Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infectious Dis 2008;198:813–7.
35. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162–71.
36. Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allerg Immunol 2007;32:57–66.
37. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419–26.
38. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Nat Acad Sci USA 2001;98:12659–64.
39. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782–95.
40. Shimabukuro-Vornhagen A, Schlosser HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, et al. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget 2014;5:4651–64.
41. Carmi Y, Engleman EG. Tumor-binding antibodies and tumor immunity. Oncotarget 2015;6:35129–30.
42. Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D. Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Develop Immunol 2010;2010:721531.
43. Deenick EK, Hasbold J, Hodgkin PD. Decision criteria for resolving isotype switching conflicts by B cells. Eur J Immunol 2005;35:2949–55.
44. Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-beta, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res 2012;31:47.
45. Guo S, Xu J, Denning W, Hel Z. Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene therapy 2009;16:1300–13.
46. Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 2008;125:229–40.